Evidence map›Paper›PMID 26821335›Full record

ArticleBasic & clinical pharmacology & toxicology2016

Vascular Reactivity Profile of Novel KCa 3.1-Selective Positive-Gating Modulators in the Coronary Vascular Bed.

Aida Oliván-Viguera, Marta Sofía Valero, Estéfano Pinilla, Sara Amor, Ángel Luis García-Villalón, Nichole Coleman, Celia Laría, Víctor Calvín-Tienza, Ángel-Luis García-Otín, José M Fernández-Fernández and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Basic & clinical pharmacology & toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Structural basis for the subtype-selective activation of KStructure (London, England : 1993) · 2026
    Article
  2. Ischemic Heart Disease and Heart Failure: Role of Coronary Ion Channels.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 3 countries.

Aida Oliván-VigueraAragon Institute of Health Sciences & IIS, Zaragoza, Spain.
Marta Sofía ValeroDepartment of Pharmacy, Faculty of Health Sciences, Universidad San Jorge, Villanueva de Gállego, Spain.
Estéfano PinillaDepartment of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Aarhus University, Aarhus, Denmark.
Sara AmorDepartment of Physiology, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Ángel Luis García-VillalónDepartment of Physiology, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Nichole ColemanDepartment of Pharmacology, University of California, Davis, CA, USA.
Celia LaríaDepartment of Pharmacy, Faculty of Health Sciences, Universidad San Jorge, Villanueva de Gállego, Spain.
Víctor Calvín-TienzaDepartment of Pharmacy, Faculty of Health Sciences, Universidad San Jorge, Villanueva de Gállego, Spain.
Ángel-Luis García-OtínDepartment of Pharmacy, Faculty of Health Sciences, Universidad San Jorge, Villanueva de Gállego, Spain.
José M Fernández-FernándezLaboratori de Fisiologia Molecular i Canalopaties, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.
M Divina MurilloDepartment of Pharmacology and Physiology, Veterinary Faculty, University of Zaragoza, Zaragoza, Spain.
José A GálvezDepartamento de Catálisis y Procesos Catalíticos, Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC - Universidad de Zaragoza, Zaragoza, Spain.
María D Díaz-de-VillegasDepartamento de Catálisis y Procesos Catalíticos, Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC - Universidad de Zaragoza, Zaragoza, Spain.
Ramón BadorreyDepartamento de Catálisis y Procesos Catalíticos, Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC - Universidad de Zaragoza, Zaragoza, Spain.
Ulf SimonsenDepartment of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Aarhus University, Aarhus, Denmark.
Luis RiveraDepartment of Physiology, Faculty of Pharmacy, Universidad Complutense de Madrid, Madrid, Spain.
Heike WulffDepartment of Pharmacology, University of California, Davis, CA, USA.
Ralf KöhlerAragon Institute of Health Sciences & IIS, Zaragoza, Spain.
Universidad de Zaragoza · ESUniversidad San Jorge · ESAarhus University · DKUniversidad Autónoma de Madrid · ESUniversity of California, Davis · USFundacion Agencia Aragonesa para la Investigacion y el Desarrollo · ESInstituto de Investigación Sanitaria Aragón · ESUniversidad Complutense de Madrid · ESUniversitat Pompeu Fabra · ES

Funding

Training Program In Basic & Translational Cardiovascular ScienceT32HL086350 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Martin Cadeiras, David A. Liem · 2008 to 2026
$7.1M
Optimization of KCa2 Channel Activators as Neuroscience Tools and Potential DrugsR21NS072585 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI WULFF, HEIKE · 2011 to 2012
$440k
NHLBI NIH HHS T32 HL086350NINDS NIH HHS R21 NS072585
6 · The paper itself

Abstract

Opening of intermediate-conductance calcium-activated potassium channels (KC a 3.1) produces membrane hyperpolarization in the vascular endothelium. Here, we studied the ability of two new KC a 3.1-selective positive-gating modulators, SKA-111 and SKA-121, to (1) evoke porcine endothelial cell KC a 3.1 membrane hyperpolarization, (2) induce endothelium-dependent and, particularly, endothelium-derived hyperpolarization (EDH)-type relaxation in porcine coronary arteries (PCA) and (3) influence coronary artery tone in isolated rat hearts. In whole-cell patch-clamp experiments on endothelial cells of PCA (PCAEC), KC a currents evoked by bradykinin (BK) were potentiated ≈7-fold by either SKA-111 or SKA-121 (both at 1 μM) and were blocked by a KC a 3.1 blocker, TRAM-34. In membrane potential measurements, SKA-111 and SKA-121 augmented bradykinin-induced hyperpolarization. Isometric tension measurements in large- and small-calibre PCA showed that SKA-111 and SKA-121 potentiated endothelium-dependent relaxation with intact NO synthesis and EDH-type relaxation to BK by ≈2-fold. Potentiation of the BK response was prevented by KC a 3.1 inhibition. In Langendorff-perfused rat hearts, SKA-111 potentiated coronary vasodilation elicited by BK. In conclusion, our data show that positive-gating modulation of KC a 3.1 channels improves BK-induced membrane hyperpolarization and endothelium-dependent relaxation in small and large PCA as well as in the coronary circulation of rats. Positive-gating modulators of KC a 3.1 could be therapeutically useful to improve coronary blood flow and counteract impaired coronary endothelial dysfunction in cardiovascular disease.

Indexed as

AnimalsBradykininCells, CulturedCoronary CirculationCoronary VesselsEndothelial CellsEndothelium, VascularGene Expression RegulationHeartIntermediate-Conductance Calcium-Activated Potassium ChannelsMaleNitric Oxide Synthase Type IIIOxazolesPatch-Clamp TechniquesPyrazolesRats5-methylnaphtho(2,1-d)oxazol-2-amineBradykininIntermediate-Conductance Calcium-Activated Potassium ChannelsNitric Oxide Synthase Type IIIOxazolesPyrazolesRNA, MessengerTRAM 34Vasodilator Agents

Identifiers

PMID26821335
PMCPMC5720859
OpenAlexW2275722185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.